AlzeCure Pharma - Catalysts on the horizon
AlzeCure remains on track with its evolution into a mid-stage biotech, having recently reported positive headline data from its Phase Ib trial for ACD440, topical TRPV1 antagonist for pain. The company also held an R&D event for its Painless platform highlighting assets for pain ACD440 and TrkA-NAM (preclinical). Upcoming Phase I data for ACD856, a cognitive enhancer for Alzheimer’s disease (AD), are expected in the coming months, while details about the start of a Phase IIa trial with ACD440 should be clarified later this year. We value AlzeCure at SEK826m or SEK21.9 per share (vs SEK19.3 per share previously).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.